Physician profile
John E Vine
NPI 1720044670
$7,904.31
in general payments reported to CMS, 2019-2025
41 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $1,169 · 2021: $1,260 · 2022: $1,477 · 2023: $1,445 · 2024: $1,053 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175 · Education: $22.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.69 |
| Education | $22.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $1,439.46 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $885.48 | 2019-2025 | Arazlo, Cabtreo, Duobrii |
| Leo Pharma INC. | $596.08 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $516.80 | 2019-2025 | Winlevi |
| Vyne Pharmaceuticals INC. | $436.63 | 2020-2021 | |
| Almirall LLC | $419.84 | 2019-2024 | Seysara |
| Merz North America, INC. | $397.34 | 2023 | Xeomin |
| Galderma Laboratories, L.P. | $385.87 | 2019-2025 | Dysport, Nemluvio |
| Epi Health, LLC | $298.34 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $250.88 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $227.84 | 2023-2024 | Zoryve |
| Incyte Corporation | $225.39 | 2021-2025 | Opzelura |
| Pfizer INC. | $189.53 | 2020-2024 | |
| Abbvie INC. | $158.09 | 2020-2023 | Rinvoq |
| Revance Therapeutics, INC. | $128.40 | 2024-2025 | Daxxify |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $120.46 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $116.45 | 2024-2025 | |
| Organogenesis INC. | $90.00 | 2020-2024 | Puraply, Cygnus Dual |
| Organon LLC | $85.16 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $84.07 | 2023-2024 | Ycanth |
| Janssen Biotech, INC. | $81.30 | 2022-2023 | Tremfya |
| Sebela Pharmaceuticals INC. | $75.33 | 2019-2022 | |
| Fidia Pharma USA INC. | $73.87 | 2024-2025 | |
| Dermira, INC. | $71.24 | 2020-2021 | |
| Amgen INC. | $69.22 | 2023-2025 | Otezla, Otezla |
| Biofrontera INC. | $67.62 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Mission Pharmacal Company | $49.80 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $48.20 | 2022-2023 | Dupixent |
| Genzyme Corporation | $43.93 | 2020-2024 | |
| Strata Skin Sciences, INC. | $40.49 | 2019-2025 | Xtrac |
| Convatec INC. | $38.07 | 2024-2025 | |
| Botanix Sb INC | $36.81 | 2025 | Sofdra |
| Encore Dermatology INC. | $28.36 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $18.45 | 2025 | Valchlor |
| Integra Lifesciences Corporation | $17.11 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Dermavant Sciences, INC. | $16.29 | 2023 | Vtama |
| Krystal Biotech INC | $16.03 | 2025 | Vyjuvek |
| Lnhc, INC | $15.67 | 2025 | Zelsuvmi |
| Triad Life Sciences INC. | $15.41 | 2022 | |
| Lilly USA, LLC | $14.93 | 2022 | |
| Allergan, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.